Benign Prostatic Hyperplasia (BPH) Screening Tool Case Finding Study in Subjects >=50 Years

PHASE4CompletedINTERVENTIONAL
Enrollment

1,679

Participants

Timeline

Start Date

May 12, 2016

Primary Completion Date

February 27, 2017

Study Completion Date

February 27, 2017

Conditions
Prostatic Hyperplasia
Interventions
OTHER

Benign prostatic enlargement (BPE)/Benign prostatic obstruction (BPO) screening tool

The BPE/BPO screening tool has been developed using the currently recommended Food and Drug Administration (FDA) 2009 guidelines for developing patient-completed questionnaires such as Patient Reported Outcomes. The tool to be used in this study in the General Practice setting has undergone validation in a urology setting to demonstrate the validity of the tool in populations with and without a definite diagnosis of BPH. Subjects who have a positive score on the BPE/BPO screening tool (total score \>=3) and meet all other eligibility requirements will be enrolled in Part I of the study.

OTHER

International Prostate Symptom Score (IPSS) screening tool

The International Prostate Symptom Score (IPSS) score is a validated tool to assess the severity of LUTS symptoms, and has similarly been used for assessing symptomatic efficacy of treatments for BPH. Subjects who have a positive score on the IPSS tool (score \>=8) and meet all other eligibility requirements will be enrolled in Part I of the study.

Trial Locations (45)

10117

GSK Investigational Site, Berlin

11009

GSK Investigational Site, Cadiz

18014

GSK Investigational Site, Granada

19300

GSK Investigational Site, Rosiers-d'Égletons

21244

GSK Investigational Site, Buchholz

39120

GSK Investigational Site, Magdeburg

41014

GSK Investigational Site, Seville

41930

GSK Investigational Site, Bormujo (Sevilla)

44115

GSK Investigational Site, Haute-Goulaine

44140

GSK Investigational Site, Aigrefeuille-sur-Maine

44277

GSK Investigational Site, Nantes

44620

GSK Investigational Site, La Montagne

46010

GSK Investigational Site, Valencia

46026

GSK Investigational Site, Valencia

58045

GSK Investigational Site, Civitella Paganico (GR)

58100

GSK Investigational Site, Grosseto

62160

GSK Investigational Site, Grenay

65439

GSK Investigational Site, Flörsheim

69469

GSK Investigational Site, Weinheim

73013

GSK Investigational Site, Galatina (LE)

73020

GSK Investigational Site, Cutrofiano (LE)

73040

GSK Investigational Site, Aradeo

73049

GSK Investigational Site, Ruffano (LE)

76000

GSK Investigational Site, Rouen

79100

GSK Investigational Site, Thouars

80339

GSK Investigational Site, Munich

123098

GSK Investigational Site, Moscow

143005

GSK Investigational Site, Odintsovo

143300

GSK Investigational Site, Naro-Fominsk

150000

GSK Investigational Site, Yaroslavl

153005

GSK Investigational Site, Ivanovo

163020

GSK Investigational Site, Arkhangelsk

195030

GSK Investigational Site, Saint Petesburg

195067

GSK Investigational Site, Saint Petersburg

195271

GSK Investigational Site, Saint Petersburg

197706

GSK Investigational Site, St'Petersburg

198328

GSK Investigational Site, Saint Petersburg

214031

GSK Investigational Site, Smolensk

426063

GSK Investigational Site, Izhevsk

432063

GSK Investigational Site, Ulyanovsk

630099

GSK Investigational Site, Novosibirsk

01744

GSK Investigational Site, Dippoldiswalde

01705

GSK Investigational Site, Freital

04329

GSK Investigational Site, Leipzig

634 050

GSK Investigational Site, Tomsk

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY